Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Allopregnanolone levels and reactivity to mental stress in premenstrual dysphoric disorder
Autore:
Girdler, SS; Straneva, PA; Light, KC; Pedersen, CA; Morrow, AL;
Indirizzi:
Univ N Carolina, Dept Psychiat, Chapel Hill, NC 27599 USA Univ N CarolinaChapel Hill NC USA 27599 chiat, Chapel Hill, NC 27599 USA Univ N Carolina, Dept Psychol, Chapel Hill, NC 27599 USA Univ N Carolina Chapel Hill NC USA 27599 ychol, Chapel Hill, NC 27599 USA Univ N Carolina, Ctr Alcohol Studies, Chapel Hill, NC 27599 USA Univ N Carolina Chapel Hill NC USA 27599 udies, Chapel Hill, NC 27599 USA
Titolo Testata:
BIOLOGICAL PSYCHIATRY
fascicolo: 9, volume: 49, anno: 2001,
pagine: 788 - 797
SICI:
0006-3223(20010501)49:9<788:ALARTM>2.0.ZU;2-9
Fonte:
ISI
Lingua:
ENG
Soggetto:
MENSTRUAL-CYCLE; RAT-BRAIN; NEUROACTIVE STEROIDS; MAJOR DEPRESSION; DOUBLE-BLIND; WOMEN; GABA(A); SENSITIVITY; ENDOCRINE; PLASMA;
Keywords:
premenstrual dysphoric disorder; allopregnanolone; cortisol; stress;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
40
Recensione:
Indirizzi per estratti:
Indirizzo: Girdler, SS Univ N Carolina, Dept Psychiat, CB 7175,Med Res Bldg A, ChapelHill, NC 27599 USA Univ N Carolina CB 7175,Med Res Bldg A Chapel Hill NC USA 27599
Citazione:
S.S. Girdler et al., "Allopregnanolone levels and reactivity to mental stress in premenstrual dysphoric disorder", BIOL PSYCHI, 49(9), 2001, pp. 788-797

Abstract

Background: This study was designed to examine basal anti stress-induced levels of the neuroactive progesterone metabolite, allopregnanolone, in women with premenstrual dysphoric disorder (PMDD) and healthy control subjects. Also, because evidence suggests that allopregnanolone negatively modulatesthe hypothalamic-pituitary-adrenal axis, plasma cortisol levels were examined. An additional goal was to investigate the relationship between premenstrual symptom severity and luteal phase allopregnanolone levels. Methods: Twenty-four women meeting prospective criterion for PMDD were compared with 12 controls during both the follicular and luteal phases of confirmed ovulatory cycles, counterbalancing phase at first testing. Plasma allopregnanolone and cortisol were sampled after an extended baseline period and again 17 min following the onset of mental stress. Owing to low follicular phase allopregnanolone levels, only luteal phase allopregnanolone and cortisol were analyzed. Results: During the luteal phase, PMDD women had significantly greater allopregnanolone levels, coupled with significantly lower cortisol levels, during both baseline and mental stress. Moreover, significantly more controls (83%) showed the expected stress-induced increases in allopregnanolone compared with PMDD women (42%). Premenstrual dysphoric disorder women also exhibited a significantly greater alllopregnanolone/progesterone ratio than control subjects, suggesting alterations in the metabolic pathways involved inthe conversion of progesterone to allopregnanolone. Finally, PMDD women with greater levels of premenstrual anxiety and irritability had significantly reduced allopregnanolone levels in the luteal phase relative to less symptomatic PMDD women. No relationship between symptom severity and allopregnanolone was observed in controls. Conclusions: These results suggest dysregulation of allopregnanolone mechanisms in PMDD and that continued investigations into a potential pathophysiologic role of allopregnanolone in PMDD are warranted. (C) 2001 Society of Biological Psychiatry.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/11/20 alle ore 21:36:25